期刊
FRONTIERS IN SURGERY
卷 9, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fsurg.2022.920976
关键词
hepatocellular carcinoma; BCLC B1 stage; liver resection; transarterial chemoembolization; safety
类别
资金
- Technology Research and Development Program of Sichuan Province [2018JY0501]
This study compared the efficacy of liver resection (LR) and transarterial chemoembolization (TACE) in treating Barcelona Clinic Liver Cancer B1 (BCLC B1) hepatocellular carcinoma. The results showed that the LR group had significantly higher survival rates and progression-free survival rates compared to the TACE group. Tumor distribution and treatment strategy were identified as independent risk factors for overall survival and progression-free survival.
BackgroundThis study aimed to compare the efficacy of liver resection (LR) and transarterial chemoembolization (TACE) in the treatment of Barcelona Clinic Liver Cancer B1 (BCLC B1) hepatocellular carcinoma. MethodsA total of 65 patients with BCLC B1 were divided into the radical (LR group) and TACE groups. Survival analysis was performed using the Kaplan-Meier method. Univariate and multivariate analyses were carried out, and the prognostic factors for survival outcomes were identified using Cox proportional analysis. ResultsThe 1-, 3-, and 5-year survival rates and the 1-, 3-, and 5-year progression-free survival (PFS) rates in the LR group (P = 0.036) were significantly higher than those in the TACE group (P = 0.027). Results of the multivariate analysis demonstrated that tumor distribution (both lobes vs. semi-liver) and treatment strategy (LR vs. TACE) were independent risk factors for the overall survival (OS) [hazard ratios (HRs): 3.926 and 0.479; P < 0.05] and PFS (HR: 3.336 and 0.465, P < 0.05). LR was associated with increased OS and PFS compared with TACE in patients with BCLC B1 hepatocellular carcinoma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据